UBC researchers develop vaccine to halt spread of West Nile Virus in birds

NewsGuard 100/100 Score

University of British Columbia researchers have developed a vaccine that may halt the spread of West Nile Virus (WNV) among common and endangered bird species.

WNV, a mosquito borne pathogen, arrived in North America in 1999 and is now endemic across the continent. In 2012 alone, WNV killed 286 people in the United States, and 42 people have died from the virus in Canada since 2002. There is currently no effective vaccine against WNV infection in humans or birds.

Common birds such as crows, ravens and jays, and endangered species such as the Greater Sage-Grouse and the Eastern Loggerhead Shrike, are also susceptible to WNV infection, with mortality rates in some species and populations as high as 100 per cent.

"West Nile Virus has been identified as a threat contributing to the extinction of some rare bird species and its presence in common birds facilitates the spread of the disease," says Joanne Young , lead author of a study recently published in PLOS ONE and a PhD student in UBC's Michael Smith Laboratories and Department of Zoology. "A bird vaccine would go a long way to helping combat these adverse effects."

Young and Prof. Wilfred Jefferies developed and tested a vaccine made from components of WNV and found it generated an effective immune response in birds. This may protect against the spread of virus not only among birds but also to other species. The team will now study the vaccine's effectiveness in protecting birds against mortality caused by the disease.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses